Brainsway Ltd. (NASDAQ:BWAY) is set to announce first quarter earning results on Wednesday 24th June 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BWAY to report 1Q20 loss of $ 0.15 per share.
For the full year, analysts anticipate top line of $ 23.02 million, while looking forward to loss of $ 0.48 per share bottom line.
The Company Outlook
Revenue for 1Q20 are expected in a range of $ 3.90 million ~ $ 4.20 million
Historical Earnings Performance
The pervious quarter 4Q19 results fallen behind street expectation, the report interpreted loss of $ 0.2 per share from the top line of $ 6.29 million, analysts anticipated loss of $ 0.12 per share
wpDataChart with provided ID not found! wpDataTable with provided ID not found!
Stock Performance
According to the previous trading day, closing price of BWAY was $ 6.25, representing a 22.55 % increase from the 52 week low of $ 5.10 and a 50.12 % decrease over the 52 week high of $ 12.53.
The company has a market capital of $ 67.90 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BWAY” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Brainsway Ltd. will be hosting a conference call at 8:30 AM eastern time on 24th June 2020, to discuss its 1Q20 financial results with the investment community. The participants may dial, +1 631-510-7495 Toll Free, (United States) or +44 (0) 2071 928000 Toll Number, with passcode : 6968612 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website edge.media-server.com/mmc/p/tq3tev8k
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimers disease, bipolar disorders, chronic pains, depressive disorders, Parkinsons diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
